Cardio-IT

Quality in CARDIOlogy
Medical Informational Technology
Working group

An open-label randomized multicenter comparative study of the efficacy and safety of Albetor® and enalaprilat in patients with uncomplicated hypertensive crisis (ALBATROS)

Journal title: 
Year: 
Authors: 
Tereshchenko S.N., Abdrakhmanov V.R., Gaponova N.I., Skibitsky V.V., Kobalava Zh.D., Bagmanova N.Kh., Grinshtein Yu.I., Shabalin V.V., Pletneva L.N., Lopatin Yu.M., Konradi A.O., Karpov R.S., Mordovin V.F., Tsymbalyuk E.V., Shutemova E.A., Kiselev A.R.
Article type: 
Full text in: 
Abstract: 
Aim. To compare the efficacy and tolerance of Albetor® and Enap (enalaprilat) in patients with es-sential hypertension (EH) and uncomplicated hypertensive crisis (HC). Subjects and methods. The study included 95 patients (36 women and 59 men) aged 57,47±8,12 years with uncomplicated hypertensive crisis and an EH history of 11,12±6,77 years. Albetor® was intravenously injected in a dose of 10–70 mg in 69 patients (Group 1) and Enap was given in a dose of 1,25 mg in 26 patients (Group 2). The efficacy criteria were a 15–25% reduction in blood pres-sure (BP) for 10–120 min. Results. The reduction in the clinical symptoms of HC and the tolerance of the drugs were compa-rable in the groups under study. Sixty-one (88.4%) of 69 patients achieved an effective BP reduc-tion by at least 15% from baseline in Group 1. The antihypertensive effect of Albetor® persisted during 6 hours of observation. 24-hour BP monitoring showed no drastic fluctuations in BP and heart rate in this group. Conclusion. Albetor® has the same antihypertensive effect as enalaprilat. The drug is well tolerated by patients and exhibits a low percentage of side effects, suggesting its safety.
Cite as: 
Tereshchenko SN, Abdrakhmanov VR, Gaponova NI, Skibitsky VV, Kobalava ZhD, Bagmanova NKh, Grinshtein YuI, Shabalin VV, Pletneva LN, Lopatin YuM, Konradi AO, Karpov RS, Mordovin VF, Tsymbalyuk EV, Shutemova EA, Kiselev AR. An open-label randomized multicenter comparative study of the efficacy and safety of Albetor® and enalaprilat in patients with uncomplicated hypertensive crisis (ALBATROS). System Hypertension 2010; (4): 48-52.

Full text: PDF